Date:
November 15, 2026 surprising genetic connection to spinal degeneration and found that an existing osteoporosis drug can prevent damaging mineral buildup in zebrafish spines. The discovery could pave the way for new treatments that slow or prevent a major cause of chronic back pain.
Share:
FULL STORY
An existing osteoporosis drug has shown surprising promise in protecting the spine from damage, raising hopes for new treatments for chronic neck and back pain. In experiments involving zebrafish, researchers found that the medication prevented abnormal mineral deposits from forming in the spine, a process that can cause spinal tissues to harden and vertebrae to fuse together.
The discovery could help scientists tackle one of the underlying causes of back pain: the gradual deterioration of the discs that cushion the bones of the spine. Researchers also identified changes in gene activity and metabolism that appear to contribute to this damage, revealing several possible targets for future treatments.
Although the findings have not yet been confirmed
Although the findings have not yet been confirmed in humans, they suggest that medications already used for other conditions could offer new ways to slow spinal degeneration. The research also demonstrates how zebrafish could help scientists investigate the causes of spinal disease and test potential therapies.
Most people experience back pain at some point in their lives, and one common cause is the deterioration of the spine’s natural shock absorbers. These structures, called intervertebral discs, sit between the vertebrae and help the spine absorb pressure, distribute weight, and move comfortably.
Over time, the discs can lose their ability to cushion the spine, a condition known as intervertebral disc degeneration (IVDD). As the discs deteriorate, they can contribute to pain, stiffness, and reduced mobility.
Despite the widespread impact and substantial economic burden
Despite the widespread impact and substantial economic burden of this condition, no medications are currently available that can stop or reverse the degenerative process. Surgery remains the only established long-term intervention for certain severe cases, creating an urgent need for treatments that address the underlying damage.
Researchers have long known that genetics influences the risk of developing spinal disc degeneration. One gene of particular interest is associated with collagen IX, a protein that helps maintain the structural integrity of spinal discs by supporting the network of fibers that holds them together. Variations affecting this gene have repeatedly been associated with disc problems that develop earlier in life.
To investigate how these genetic changes contribute to spinal damage, scientists at the Universities of Edinburgh and Bristol turned to zebrafish. They studied fish that had been bred without a functioning copy of the gene, allowing them to observe how its absence affected the spine as the animals grew older.
A Hidden Process Causes the Spine To Harden
The results revealed striking similarities between the genetically
The results revealed striking similarities between the genetically altered zebrafish and people with degenerative spinal disease.
As the fish aged, abnormal mineral deposits accumulated in the tissues separating their vertebrae. This process, known as mineralization, involves minerals collecting in tissues where they do not normally belong. In the spine, the buildup can cause normally flexible structures to become unusually rigid, much like unwanted bone forming in the wrong location.
The researchers also observed spinal fusion, in which neighboring vertebrae become joined together. Such changes can interfere with the spine’s normal flexibility and movement.
Importantly, the scientists discovered that the damage began
Importantly, the scientists discovered that the damage began well before the mineral deposits appeared. An underlying layer that provides structural support during spinal development started to break down first, suggesting that deterioration of this protective framework may set the stage for later hardening.
This finding could help explain how genetic changes initiate a chain reaction that eventually damages the spine.
Surprising Links to Fat Metabolism and Vitamin A
To understand what was happening at the molecular level, the team examined patterns of gene activity in the zebrafish. This allowed them to identify biological processes that had become unusually active or disrupted as spinal degeneration developed.
Several unexpected connections emerged.
The researchers found alterations in fat metabolism,
The researchers found alterations in fat metabolism, the processes through which the body breaks down, stores, and uses fats. They also detected disturbances in a cellular signaling system called mTOR, which helps regulate cell growth, metabolism, and responses to nutrients.
Additional changes involved phosphate regulation and vitamin A signaling. Phosphate is an essential mineral involved in building bones and teeth, but its accumulation in the wrong tissues can contribute to abnormal hardening. Vitamin A signaling helps control how cells develop and function.
Together, these findings suggest that spinal disc degeneration involves more than the gradual wearing down of tissues. Changes in how cells process nutrients, regulate growth, and handle minerals may also play important roles.
An Osteoporosis Drug Blocks Spinal Mineral Buildup
One of the most promising discoveries came when
One of the most promising discoveries came when researchers tested ways to reduce the spinal abnormalities.
A medication belonging to a class of drugs called bisphosphonates successfully blocked the abnormal mineral buildup in the zebrafish. Bisphosphonates are already used to treat osteoporosis, a condition in which bones become weaker and more vulnerable to fractures. These medications help protect bones by slowing the processes that break down bone tissue.
The finding is especially intriguing because it suggests that a treatment already used in patients might also help researchers develop therapies for spinal degeneration.
The team identified other approaches that reduced spinal
The team identified other approaches that reduced spinal damage. Limiting how much food the zebrafish consumed led to fewer spinal fusions, as did medications that suppressed fat metabolism.
These results point toward fat metabolism and phosphate regulation as potentially important targets for future drugs.
However, the experiments were conducted in zebrafish, not humans. More research will be needed to determine whether the same biological mechanisms operate in people and whether targeting them can safely prevent or slow spinal disc degeneration. The dietary findings also do not establish that restricting food intake can prevent spinal damage in humans.
New Hope for Chronic Back Pain Treatments
The study was published in the journal Communications
The study was published in the journal Communications Biology and received support from Arthritis UK and BBSRC.
Dr. Erika Kague, who led the research at the University of Edinburgh’s Institute of Genetics and Cancer, emphasized the potential significance of identifying treatments that target the underlying causes of spinal damage.
“For decades, surgery has been the only real answer for disc disease. By understanding the biology that drives the spine to harden, our zebrafish studies point to several ways of slowing it down, including a drug already used safely in patients. There’s more work to do, but for a condition that’s affected people for generations without a treatment in sight, this is super exciting.”
The findings could be particularly important
The findings could be particularly important for the millions of people who live with persistent back pain and have limited options for preventing their condition from worsening.
Dr. Caroline Aylott, Head of Research Delivery at Arthritis UK, highlighted the potential benefits for patients.
“For the 9.5 million people across the UK living with back pain this research brings fresh hope that potential new therapeutic approaches are on the horizon.
We are proud to fund research
“We are proud to fund research that is unlocking the science behind the processes leading to spinal disc degeneration. Back pain is one of the UK’s most common conditions that has blighted millions over generations. Dr. Erika Kague and her team at the University of Edinburgh have uncovered important genetic evidence that could pave the way for new treatments, bringing us one step closer to a future where fewer people have to live with the daily pain and challenges that back pain can bring.”
The research also illustrates the broader value of studying basic biological processes to understand diseases that affect large numbers of people.
Dr. Jef Grainger, Executive Director for Bioscience Advancing Knowledge at BBSRC, said:
“This research shows how publicly funded discovery bioscience can generate the knowledge needed to address major health challenges. By revealing new knowledge of how healthy biological processes break down in aging-related spinal disc degeneration, the study opens up promising avenues for future treatment development. It’s a great example of how BBSRC-supported research helps turn scientific discovery into knowledge and innovations that have the potential to improve people’s lives.”
For a condition that affects millions and has
For a condition that affects millions and has no approved drug capable of stopping its progression, these early findings offer an encouraging starting point for developing treatments that could one day protect the spine before serious damage occurs.
Materials provided by University of Edinburgh. Note: Content may be edited for style and length.
- Erika Kague, Beatriz Larraz Prieto, Renata A. Raele, Bianca Ventura Fernandes, Joanna Moss, Chrissy L. Hammond. Targeted modulation of phosphate and lipid metabolism reduces ligament mineralization in col9a1b deficient zebrafish. Communications Biology, 2026; DOI: 10.1038/s42003-026-10702-1
University of Edinburgh. “A common osteoporosis drug blocked spinal damage in a surprising new study.” ScienceDaily. ScienceDaily, 15 November 2026. <www.sciencedaily.com/releases/2026/11/261113232105.htm>.
University of Edinburgh. (2026, November 15). A common osteoporosis drug blocked spinal damage in a surprising new study. ScienceDaily. Retrieved November 15, 2026 from www.sciencedaily.com/releases/2026/11/261113232105.htm
University of Edinburgh. “A common osteoporosis drug blocked spinal damage in a surprising new study.” ScienceDaily. www.sciencedaily.com/releases/2026/11/261113232105.htm (accessed November 15, 2026).
RELATED STORIES
